{"classes":[{"categories":[{"measurements":[{"comment":"NA = not estimable as there were not enough events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Duration of MMR is defined as the time between the date of the first MMR and the date of confirmed loss of MMR (i.e. the earliest of confirmed loss of MMR, CML-related death or progression to AP or BC). Participants without loss of MMR were censored at the last molecular assessment date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients resistant or intolerant to either imatinib or dasatinib","id":"OG000","title":"Resistant/Intolerant Ph+ CML in CP"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS): All patients who received at least one dose of study medication.","reportingStatus":"POSTED","timeFrame":"from MMR until confirmed loss of MMR (Assessed up to 66 cycles)","title":"Duration of First MMR Among Patients Who Were Resistant or Intolerant to Either Imatinib or Dasatinib Who Achieved MMR","type":"SECONDARY","unitOfMeasure":"months"}